Literature DB >> 28752524

Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.

S Petta1, V W-S Wong2,3, C Cammà1, J-B Hiriart4, G L-H Wong2,3, J Vergniol4, A W-H Chan5, V Di Marco1, W Merrouche4, H L-Y Chan2,3, F Marra6, B Le-Bail7,8, U Arena6, A Craxì1, V de Ledinghen4,7.   

Abstract

BACKGROUND: The accuracy of available non-invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still limited. AIM: To assess the diagnostic performance of paired or serial combination of non-invasive tools in NAFLD patients.
METHODS: We analysed data from 741 patients with a histological diagnosis of NAFLD. The GGT/PLT, APRI, AST/ALT, BARD, FIB-4, and NAFLD Fibrosis Score (NFS) scores were calculated according to published algorithms. Liver stiffness measurement (LSM) was performed by FibroScan.
RESULTS: LSM, NFS and FIB-4 were the best non-invasive tools for staging F3-F4 fibrosis (AUC 0.863, 0.774, and 0.792, respectively), with LSM having the highest sensitivity (90%), and the highest NPV (94%), and NFS and FIB-4 the highest specificity (97% and 93%, respectively), and the highest PPV (73% and 79%, respectively). The paired combination of LSM or NFS with FIB-4 strongly reduced the likelihood of wrongly classified patients (ranging from 2.7% to 2.6%), at the price of a high uncertainty area (ranging from 54.1% to 58.2%), and of a low overall accuracy (ranging from 43% to 39.1%). The serial combination with the second test used in patients in the grey area of the first test and in those with high LSM values (>9.6 KPa) or low NFS or FIB-4 values (<-1.455 and <1.30, respectively) overall increased the diagnostic performance generating an accuracy ranging from 69.8% to 70.1%, an uncertainty area ranging from 18.9% to 20.4% and a rate of wrong classification ranging from 9.2% to 11.3%.
CONCLUSION: The serial combination of LSM with FIB-4/NFS has a good diagnostic accuracy for the non-invasive diagnosis of severe fibrosis in NAFLD.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28752524     DOI: 10.1111/apt.14219

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Heather Mary-Kathleen Kosick; Aline Keyrouz; Oyedele Adeyi; Giada Sebastiani; Keyur Patel
Journal:  Dig Dis Sci       Date:  2021-01-03       Impact factor: 3.199

Review 2.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

3.  Serum immunoglobulin A levels and non-alcoholic fatty liver disease.

Authors:  Evan Elias; Julia Uhanova; Qian Li; Manna Zhang; Gerald Minuk
Journal:  Can Liver J       Date:  2018-12-25

4.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

Review 5.  The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Authors:  Maya Balakrishnan; Rohit Loomba
Journal:  J Clin Gastroenterol       Date:  2020-02       Impact factor: 3.062

6.  NON-INVASIVE ASSESSMENT OF LIVER STEATOSIS AND FIBROSIS USING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER IN TYPE 2 DIABETES PATIENTS.

Authors:  A Sima; I Sporea; R Timar; M Vlad; A Braha; A Popescu; S Nistorescu; R Mare; R Sirli; A Albai; O Albai; L Diaconu; T Sorescu; S Popescu; L Sima
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

7.  Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study.

Authors:  K S Vinod; Lal P Madathil; Pushparaja Shetty; Harsimran Kaur; Mimansha Patel; Abhishek Gouraha
Journal:  J Int Soc Prev Community Dent       Date:  2018-04-30

8.  Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Wei-Yu Kao; I-Wei Chang; Chi-Long Chen; Chien-Wei Su; Sheng Uei Fang; Jui-Hsiang Tang; Chun-Chao Chang; Yu-Jia Chang; Weu Wang
Journal:  Obes Surg       Date:  2020-04       Impact factor: 4.129

9.  Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.

Authors:  Ayşegül Avcu; Eda Kaya; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.852

Review 10.  Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Authors:  Yasushi Honda; Masato Yoneda; Kento Imajo; Atsushi Nakajima
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.